fb-pixel Skip to main content
Mass. coronavirus at a glance
High Med. Low
.
Select a county:
COVID 19 community level from CDC:
.
Case Rate per 100,000 population:
.
New COVID-19 admissions per 100,000:
.
Total cases:
Total deaths:

Recent coronavirus news & features

More coronavirus stories


Repeat coronavirus infections can still be dangerous, study suggests

For people who have endured one bout of COVID-19, a question looms: How protected are they from bad outcomes if they’re infected again? Not as much as some might think, according to a study from the Department of Veterans Affairs of nearly 41,000 people who suffered reinfection.

See how many people have received a COVID-19 vaccine in your Mass. town

See who has been vaccinated in your community.

Masks cut COVID-19 spread in schools, study finds

A research paper details a so-called natural experiment that occurred when all but two school districts in the greater Boston area lifted mask requirements in the spring.

COVID hospitalizations are rising in kids under 6 months, CDC director Walensky says

COVID-19 hospitalizations are rising among babies under 6 months old, and the US Centers for Disease Control and Prevention is urging mothers to get vaccinated to reduce the risk of infection in those not yet eligible for shots, Director Rochelle Walensky said.

Pfizer dominates the COVID drug market. This Watertown biotech wants to change that.

Enanta Pharmaceuticals has started a clinical trial of a pill that it says could be safer than the pharma giant's Paxlovid.

COVID patients coming off ventilators can take weeks to regain consciousness

For years, Dr. Nicholas Schiff and Dr. Emery Brown have been developing theories about what happens in the brain during comas, sleep, and anesthesia. Now they turned their efforts to COVID. Their search for clues brought them unexpectedly to studies of turtles.

CDC data show sharp increase in COVID cases caused by BQ.1 and BQ.1.1 subvariants

The CDC estimates that immunity-evading BQ.1 and BQ.1.1 subvariants now account for 14 and 13.1 percent of the nation’s COVID-19 cases, respectively — more than a quarter.

Hate needles? Flu vaccines of the future could be skin patches delivered to your door.

Vaxess, a Cambridge startup with ties to Harvard, MIT, and Tufts, raised $27 million to test its technology in clinical trials after developing the idea for more than a decade.